| scholarly article | Q13442814 |
| P356 | DOI | 10.3810/PGM.2010.11.2217 |
| P953 | full work available at URL | http://www.tandfonline.com/doi/pdf/10.3810/pgm.2010.11.2217 |
| P698 | PubMed publication ID | 21084776 |
| P5875 | ResearchGate publication ID | 47812104 |
| P50 | author | John Hawboldt | Q91539652 |
| P2093 | author name string | Annie Brooks | |
| Mazen S. Bader | |||
| P2860 | cites work | Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study | Q24617818 |
| Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America | Q28273894 | ||
| National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. | Q30227387 | ||
| Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies | Q31048370 | ||
| Fluoroquinolone resistance during 2000-2005: an observational study | Q33337504 | ||
| Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment. | Q33515785 | ||
| Bacteremia complicating gram-negative urinary tract infections: a population-based study | Q33738237 | ||
| Antimicrobial susceptibility of bacteria isolated from urine samples obtained from nursing home residents | Q33835311 | ||
| Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. | Q34096605 | ||
| Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection | Q34109281 | ||
| Does this woman have an acute uncomplicated urinary tract infection? | Q34646061 | ||
| Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance | Q35858947 | ||
| Newer carbapenems for urinary tract infections | Q35885913 | ||
| Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli | Q36452576 | ||
| Current challenges in the treatment of complicated urinary tract infections and prostatitis | Q36466656 | ||
| State of the art: imaging of renal infections | Q36743627 | ||
| Comparative review of the carbapenems | Q36815085 | ||
| Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis | Q37052814 | ||
| Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer | Q37055211 | ||
| Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection | Q37101552 | ||
| Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. | Q37217108 | ||
| Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary | Q37302749 | ||
| Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis | Q37333147 | ||
| AmpC beta-lactamases | Q37366249 | ||
| Doripenem monohydrate, a broad-spectrum carbapenem antibiotic | Q37401472 | ||
| The use of carbapenems in the treatment of serious infections | Q37555757 | ||
| The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation Research Consensus Statement. January 27-29, 1992 | Q68012968 | ||
| A reassessment of the importance of "low-count" bacteriuria in young women with acute urinary symptoms | Q72893262 | ||
| Comparison of test characteristics of urine dipstick and urinalysis at various test cutoff points | Q77070533 | ||
| Therapeutic options for infections due to vancomycin-resistant enterococci | Q83620710 | ||
| Emerging drugs for bacterial urinary tract infections | Q84457088 | ||
| The newer fluoroquinolones | Q84893521 | ||
| Role of old antibiotics in multidrug resistant bacterial infections | Q37607316 | ||
| Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices | Q37694529 | ||
| Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. | Q37749111 | ||
| Development of quality indicators for the antibiotic treatment of complicated urinary tract infections: a first step to measure and improve care | Q39064898 | ||
| Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities | Q39923839 | ||
| Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis | Q42000458 | ||
| Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States | Q43007779 | ||
| Urinary tract infection in male general practice patients: uropathogens and antibiotic susceptibility | Q43056478 | ||
| A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice | Q43067192 | ||
| Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation | Q43105699 | ||
| Changing prevalence of Escherichia coli with CTX-M-type extended-spectrum beta-lactamases in outpatient urinary E. coli between 2003 and 2008. | Q43130801 | ||
| Changes in aac(6')-Ib-cr prevalence and fluoroquinolone resistance in nosocomial isolates of Escherichia coli collected from 1991 through 2005. | Q43169864 | ||
| Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997-2007. | Q43219801 | ||
| CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. | Q43293884 | ||
| Activity of levofloxacin and ciprofloxacin against urinary pathogens | Q43648069 | ||
| Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis | Q44721039 | ||
| Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy | Q44901161 | ||
| Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli | Q46420220 | ||
| Nitrofurantoin: the return of an old friend in the wake of growing resistance | Q46461214 | ||
| A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis | Q46777303 | ||
| Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. | Q46809473 | ||
| Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase | Q46862305 | ||
| Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006. | Q46879516 | ||
| Blood cultures for women with uncomplicated acute pyelonephritis: are they necessary? | Q47589560 | ||
| Community-onset urinary tract infections: a population-based assessment. | Q51102559 | ||
| Are blood cultures necessary in the management of women with complicated pyelonephritis? | Q51282787 | ||
| A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. | Q51736675 | ||
| Clinical investigation of isolated bacteria from urinary tracts of hospitalized patients and their susceptibilities to antibiotics. | Q51840004 | ||
| The clinical impact of bacteremia in complicated acute pyelonephritis. | Q53594518 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | urinary tract infection | Q221668 |
| bacterial drug resistance | Q64924127 | ||
| antimicrobial resistance | Q63391344 | ||
| P304 | page(s) | 7-15 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Postgraduate Medicine | Q7234297 |
| P1476 | title | Management of complicated urinary tract infections in the era of antimicrobial resistance | |
| Management of Complicated Urinary Tract Infections in the Era of Antimicrobial Resistance | |||
| P478 | volume | 122 |
| Q89597677 | A Smart Drug Delivery System Based on Biodegradable Chitosan/Poly(allylamine hydrochloride) Blend Films |
| Q93273823 | A guide for urogynecologic patient care utilizing telemedicine during the COVID-19 pandemic: review of existing evidence |
| Q26783911 | Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis |
| Q36095704 | Characteristics and Antibiotic Resistance of Urinary Tract Pathogens Isolated From Punjab, Pakistan |
| Q42437660 | Clinical factors associated with shock in bacteremic UTI. |
| Q53830349 | Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study. |
| Q33616113 | Cystitis: from urothelial cell biology to clinical applications |
| Q35022748 | Declines in outpatient antimicrobial use in Canada (1995-2010). |
| Q38888992 | Effect of Utipro(®) (containing gelatin-xyloglucan) against Escherichia coli invasion of intestinal epithelial cells: results of an in vitro study. |
| Q99576076 | Emphysematous Pyelonephritis in a Diabetic Patient with Remarkable Radiological Findings and Excellent Outcome without Surgical Intervention or Drainage |
| Q40358195 | Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections. |
| Q37263841 | Identification of extended-spectrum-β-lactamase-positive Klebsiella pneumoniae urinary tract isolates harboring KPC and CTX-M β-lactamases in nonhospitalized patients |
| Q64898853 | Oral and intravenous fosfomycin in complicated urinary tract infections. |
| Q36204123 | Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections |
| Q58741632 | Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections |
| Q35385843 | Propensity-matched analysis to compare the therapeutic efficacies of cefuroxime versus cefotaxime as initial antimicrobial therapy for community-onset complicated nonobstructive acute pyelonephritis due to Enterobacteriaceae infection in women |
| Q41099994 | Prophylactic efficacy of cephamycin plus fluoroquinolones in high risk patients on inhibiting infectious complications after transrectal prostate biopsy |
| Q40066430 | Prospective cohort study of risk factors for extended-spectrum ß-lactamase-producing Escherichia coli urinary tract infections in elderly patients admitted to hospital. |
| Q36992856 | Recommended Initial Antimicrobial Therapy for Emphysematous Pyelonephritis: 51 Cases and 14-Year-Experience of a Tertiary Referral Center. |
| Q44999503 | Relationship between urinary tract infection categorization and pathogens' antimicrobial susceptibilities |
| Q37177518 | Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING) |
| Q60301100 | Risk factors and prognosis of complicated urinary tract infections caused by in hospitalized patients: a retrospective multicenter cohort study |
| Q90642148 | Study of Culture and Sensitivity Patterns of Urinary Tract Infections in Patients Presenting with Urinary Symptoms in a Tertiary Care Hospital |
| Q36791550 | Surveillance of multidrug resistant uropathogenic bacteria in hospitalized patients in Indian |
| Q58772829 | The rates of quinolone, trimethoprim/sulfamethoxazole and aminoglycoside resistance among Enterobacteriaceae isolated from urinary tract infections in Azerbaijan, Iran |
| Q37899640 | Tigecycline treatment for urinary tract infections: case report and literature review |
| Q36386410 | Toxoplasma gondii and cognitive deficits in schizophrenia: an animal model perspective |
| Q90182172 | Urine analysis with dipstick test in asymptomatic 7-year-old children |
| Q44478508 | Urine flow cytometry as a primary screening method to exclude urinary tract infections |
Search more.